Quarterly report [Sections 13 or 15(d)]

Fair Value Measurements (Tables)

v3.25.3
Fair Value Measurements (Tables)
9 Months Ended
Sep. 30, 2025
Fair Value Measurements  
Schedule of financial assets and liabilities measured at fair value on a recurring basis

The following tables set forth the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Fair Value Measurements as of September 30, 2025 using:

​

​

Quoted Prices in

​

Significant Other

​

Significant

​

​

​

​

​

Active Markets for

​

Observable

​

Unobservable

​

​

​

​

​

Identical Assets

​

Inputs

​

Inputs

​

​

​

​

​

(Level 1)

​

(Level 2)

​

(Level 3)

​

Total

Assets:

​

​

​

​

​

​

​

​

​

​

​

​

Cash equivalents:

​

​

​

​

​

​

​

​

​

​

​

​

Money market funds

​

$

8,805

​

$

—

​

$

—

​

$

8,805

U.S. treasury bills

​

​

26,202

​

​

—

​

​

—

​

​

26,202

Total cash equivalents

​

​

35,007

​

​

—

​

​

—

​

​

35,007

Investment in equity securities

​

​

1,521

​

​

—

​

​

—

​

​

1,521

Exarafenib milestone asset (Note 6)

​

​

—

​

​

—

​

​

3,500

​

​

3,500

Castle Creek PRV Interest (Note 4)

​

​

—

​

​

—

​

​

—

​

​

—

Castle Creek warrants (Note 4)

​

​

—

​

​

—

​

​

595

​

​

595

Total financial assets

​

$

36,528

​

$

—

​

$

4,095

​

$

40,623

Liabilities:

​

​

​

​

​

​

​

​

​

​

​

​

Exarafenib milestone contingent consideration (Note 6)

​

$

—

​

$

—

​

$

3,500

​

$

3,500

Total financial liabilities

​

$

—

​

$

—

​

$

3,500

​

$

3,500

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Fair Value Measurements as of December 31, 2024 using:

​

​

Quoted Prices in

​

Significant Other

​

Significant

​

​

​

​

​

Active Markets for

​

Observable

​

Unobservable

​

​

​

​

​

Identical Assets

​

Inputs

​

Inputs

​

​

​

​

​

(Level 1)

​

(Level 2)

​

(Level 3)

​

Total

Assets:

​

​

​

​

​

​

​

​

​

​

​

​

Cash equivalents:

​

​

​

​

​

​

​

​

​

​

​

​

Money market funds

​

$

72,304

​

$

—

​

$

—

​

$

72,304

U.S. treasury bills

​

​

20,367

​

​

—

​

​

—

​

​

20,367

Total cash equivalents

​

​

92,671

​

​

—

​

​

—

​

​

92,671

Investment in equity securities

​

​

3,529

​

​

—

​

​

—

​

​

3,529

Exarafenib milestone asset (Note 6)

​

​

—

​

​

—

​

​

3,214

​

​

3,214

Total financial assets

​

$

96,200

​

$

—

​

$

3,214

​

$

99,414

Liabilities:

​

​

​

​

​

​

​

​

​

​

​

​

Exarafenib milestone contingent consideration (Note 6)

​

$

—

​

$

—

​

$

3,214

​

$

3,214

Total financial liabilities

​

$

—

​

$

—

​

$

3,214

​

$

3,214